CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
利用趋化因子系统使 CAR-T 细胞归巢至实体瘤
英文原题：Harnessing the chemokine system to home CAR-T cells into solid tumors.
查看英文原题
Harnessing the chemokine system to home CAR-T cells into solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法被誉为免疫治疗领域的一项突破，但迄今其成功主要局限于血液系统恶性肿瘤。通过利用趋化因子系统，并考虑肿瘤微环境中的趋化因子表达谱，有望引导 CAR-T 细胞归巢至肿瘤，促进其直接杀伤肿瘤细胞，从而克服实体瘤中有效诱导 CAR-T 细胞应答的一项主要障碍。
展开英文摘要原文
CAR-T cell therapy has been heralded as a breakthrough in the field of immunotherapy, but to date, this success has been limited to hematological malignancies. By harnessing the chemokine system and taking into consideration the chemokine expression profile in the tumor microenvironment, CAR-T cells may be homed into tumors to facilitate direct tumor cell cytolysis and overcome a major hurdle in generating effective CAR-T cell responses to solid cancers.
论文信息
- 作者
- Foeng J、Comerford I、McColl SR
- 单位
- Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, SA 5005, Australia.Australia
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cell reports. Medicine2022 Mar 15
- 原文标识
- PubMed 35492880 · DOI 10.1016/j.xcrm.2022.100543
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →